Key Market Indicators
Sales of diabetes medicines in Slovenia are projected to reach around $50 million by 2026, up from $46 million in 2021. This marks an average annual growth rate of 1.6% since 2012, when the market stood at $6.5 million. Slovenia ranked 21st in 2021, with New Zealand coming out on top with sales of $46 million. Canada, Spain and Italy followed in second, third and fourth place respectively. Imports of insulin to Slovenia are expected to reach $20 million by 2026, up from $18 million in 2021. This represents an average annual growth rate of 1.9% since 1999, when the demand was just $6.9 million. Exports of insulin from Slovenia are forecast to reach $547,000 by 2026, up from $508,000 in 2021. This translates to an average annual growth rate of 1.4% since 1999, when the supply stood at $4.7 million. Slovenia ranked 36th in 2021, with South Africa leading the way with exports of $508,000. France, Italy and China followed in second, third and fourth place respectively.
